The Journal of Practical Medicine >
Proteomic profiling and functional analysis of differentially expressed proteins in lung cancer coexistent with pulmonary tuberculosis
Received date: 2024-02-25
Online published: 2024-07-09
Objective This study aims to analyze the proteomic characteristics of peripheral blood in patients with lung cancer coexistent with pulmonary tuberculosis （LC?PTB）， identify the differential proteins compared with lung cancer （LC） patients， and conduct functional analysis on these proteins. Methods The study included 8 LC?PTB patients and 10 LC patients. The LC patients were newly diagnosed and confirmed by pathology and did not receive any anti?tumor treatment before， while the PTB patients were Mycobacterium tuberculosis positive at the time of sampling. Liquid chromatography?tandem mass spectrometry （LC?MS/MS） was applied to perform proteomic mass spectrometry to assess the differential proteins， and then functional analysis was conducted via bioinformatics. Results A total of 5，185 proteins were detected between two groups. Through differential expression screening， 190 proteins （58 upregulated and 132 downregulated） were identified to be differentially expressed. Subcellular localization analysis revealed that the differential proteins were mainly concentrated in the cytoplasm， nucleus， and extracellular matrix. KEGG pathway and GO analysis showed the roles of differential proteins in biological processes including immune response， metabolism， and secretion regulation. Protein interaction network analysis highlighted the importance of SORT1， SAR1B， RPS6KB1， VWF， SHC1， SRPRB， CTSD， TARDBP， RPLP0， PSMA2， RPS6， XPO1， PRKACB， and HLA?DRB1 in LC?PTB. Additionally， the expression changes in proteins like ADA2， MAP3K1， and GLS2 might be closely associated with the development of LC?PTB. Conclusions The proteomic profile comprehensively described the proteomic characteristics of LC?PTB and identified numerous differentially expressed proteins， which could provide further clues for research on biological mechanism of LC?PTB.
Wendi ZHOU , Jiamin LIN , Daichen JU , Qi WANG , Jialou ZHU , Ning SU , Jinxing. HU . Proteomic profiling and functional analysis of differentially expressed proteins in lung cancer coexistent with pulmonary tuberculosis[J]. The Journal of Practical Medicine, 2024 , 40(13) : 1814 -1821 . DOI: 10.3969/j.issn.1006-5725.2024.13.009
| 1 | SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin， 2021， 71（3）： 209-249. doi:10.3322/caac.21660 |
| 2 | WANG C， WANG Z， WANG G， et al. COVID-19 in early 2021： current status and looking forward［J］. Signal Transduct Target Ther， 2021， 6（1）： 114. doi:10.1038/s41392-021-00527-1 |
| 3 | BAGCCHI S. WHO′s Global Tuberculosis Report 2022［J］. Lancet Microbe， 2023， 4（1）： e20. doi:10.1016/s2666-5247(22)00359-7 |
| 4 | 吴惠忠，胡锦兴. 结核病传播研究进展［J］. 实用医学杂志， 2023， 39（19）： 2424-2427. doi:10.3969/j.issn.1006-5725.2023.19.002 |
| 5 | HWANG S Y， KIM J Y， LEE H S， et al. Pulmonary Tuberculosis and Risk of Lung Cancer： A Systematic Review and Meta-Analysis［J］. J Clin Med，2022， 11（3）：765. doi:10.3390/jcm11030765 |
| 6 | ELHADI M， KHALED A， MSHERGHI A. Infectious diseases as a cause of death among cancer patients： a trend analysis and population-based study of outcome in the United States based on the Surveillance， Epidemiology， and End Results database［J］. Infect Agent Cancer， 2021， 16（1）： 72. doi:10.1186/s13027-021-00413-z |
| 7 | XIONG K， SUN W， HE Y， et al. Advances in molecular mechanisms of interaction between Mycobacterium tuberculosis and lung cancer： a narrative review.［J］. Transl Lung Cancer Res，2021， 10（10）： 4012-4026. doi:10.21037/tlcr-21-465 |
| 8 | 中华人民共和国国家卫生和计划生育委员会. 结核病分类（ws196—2017） ［J］. 新发传染病电子杂志， 2018（3）：191-192. doi:10.3877/j.issn.2096-2738.2018.03.019 |
| 9 | YANG L， ZHUANG L， YE Z， et al. Immunotherapy and biomarkers in patients with lung cancer with tuberculosis： Recent advances and future Directions［J］. iScience， 2023， 26（10）： 107881. doi:10.1016/j.isci.2023.107881 |
| 10 | 崔兰兰，张革， 徐邦牢. 牙龈卟啉单胞菌感染性食管鳞癌细胞外泌体蛋白组学分析［J］. 实用医学杂志， 2023， 39（17）： 2171-2175. doi:10.3969/j.issn.1006-5725.2023.17.004 |
| 11 | LIU Q， ZHANG J， GUO C， et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies［J］. Cell， 2024， 187（1）： 184-203.e28. doi:10.1016/j.cell.2023.12.004 |
| 12 | GILLETTE M A， SATPATHY S， CAO S， et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma［J］. Cell， 2020， 182（1）： 200-225.e35. |
| 13 | ZHANG M， XIE Y， LI S， et al. Proteomics Analysis of Exosomes From Patients With Active Tuberculosis Reveals Infection Profiles and Potential Biomarkers［J］. Front Microbiol， 2022， 12： 800807. doi:10.3389/fmicb.2021.800807 |
| 14 | KALJAS Y， LIU C， SKALDIN M， et al. Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells［J］. Cell Mol Life Sci， 2017， 74（3）： 555-570. doi:10.1007/s00018-016-2357-0 |
| 15 | DELEMARRE E M， VAN HOORN L， BOSSINK A W J， et al. Serum biomarker profile including CCL1， CXCL10， VEGF， and adenosine deaminase activity distinguishes active from remotely acquired latent tuberculosis［J］. Front Immunol， 2021， 12： 725447. doi:10.3389/fimmu.2021.725447 |
| 16 | NAGY á， LáNCZKY A， MENYHáRT O， et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets［J］. Sci Rep， 2018， 8（1）： 9227. doi:10.1038/s41598-018-27521-y |
| 17 | WANG L， LONDONO L M， COWELL J， et al. Targeting adenosine with adenosine deaminase 2 to inhibit growth of solid tumors［J］. Cancer Res， 2021， 81（12）： 3319-3332. doi:10.1158/0008-5472.can-21-0340 |
| 18 | LI H， CAO W， CHEN S， et al. Comparative interleukins and chemokines analysis of mice mesenchymal stromal cells infected with mycobacterium tuberculosis H37Rv and H37Ra［J］. Arch Biochem Biophys， 2023， 744： 109673. doi:10.1016/j.abb.2023.109673 |
| 19 | XUE Z， VIS D J， BRUNA A， et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models［J］. Cell Res， 2018， 28（7）： 719-729. doi:10.1038/s41422-018-0044-4 |
| 20 | LIU C， WANG S， ZHU S， et al. MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitro［J］. Springerplus， 2016， 5： 11. doi:10.1186/s40064-015-1597-z |
| 21 | JIN J， J-K BYUN， Y-K CHOI， et al. Targeting glutamine metabolism as a therapeutic strategy for cancer［J］. Exp Mol Med， 2023， 55（4）： 706-715. doi:10.1038/s12276-023-00971-9 |
| 22 | KOEKEN V A C M， LACHMANDAS E， RIZA A， et al. Role of glutamine metabolism in host defense against mycobacterium tuberculosis infection［J］. J Infect Dis， 2019， 219（10）： 1662-1670. doi:10.1093/infdis/jiy709 |
| 23 | VáZQUEZ C L， RODGERS A， HERBST S， et al. The proneurotrophin receptor sortilin is required for Mycobacterium tuberculosis control by macrophages［J］. Sci Rep， 2016， 6： 29332. doi:10.1038/srep29332 |
| 24 | AL-AKHRASS H， NAVES T， VINCENT F， et al. Sortilin limits EGFR signaling by promoting its internalization in lung cancer［J］. Nat Commun， 2017， 8（1）： 1182. doi:10.1038/s41467-017-01172-5 |
| 25 | SCHAAFSMA E， FUGLE C M， WANG X， et al. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy［J］. Br J Cancer， 2021， 125（3）： 422-432. doi:10.1038/s41416-021-01400-2 |
| 26 | SENOSAIN M F， ZOU Y， NOVITSKAYA T， et al. HLA-DR cancer cells expression correlates with T cell infiltration and is enriched in lung adenocarcinoma with indolent behavior［J］. Sci Rep， 2021， 11（1）： 14424. doi:10.1038/s41598-021-93807-3 |
| 27 | YANG P L， HE X J， ZANG Q J， et al. Association of human leukocyte antigen DRB1 polymorphism and tuberculosis： a meta-analysis［J］. Int J Tuberc Lung Dis， 2016， 20（1）： 121-128. doi:10.5588/ijtld.14.0930 |
/
| 〈 |
|
〉 |